Cyclerion reports Q1 net loss $13.0M; CY6463 MELAS data expected Q2 2022

Cyclerion Therapeutics, Inc.

2023-Q1 EPS reported -$0.30 revenue$711,000

Net loss of $13.0M in Q1 2022 vs $13.4M in Q1 2021; cash balance $41M (down from $54M).
R&D expenses rose to $9.7M from $8.0M due to external research costs; G&A fell to $4.0M from $5.4M.
MELAS study enrollment closed; topline data expected Q2 2022.
CIAS study enrollment closed; topline data expected Q3 2022.
Alzheimer's disease with vascular pathology (ADv) study enrollment ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.